Research Highlights: Children who had higher blood pressure at age 7 were more likely to die early from cardiovascular disease by their mid-50s. The risk was highest for children whose blood pressure measurements were in the top 10% for their age, sex and height. Both elevated blood pressure (90-94th percentile) and hypertension (≥95th percentile) were linked with about a 40% to 50% higher risk of early cardiovascular death in adulthood. Researchers said their findings show why it’s important to regularly check children’s blood pressure and to help them develop heart-healthy habits early that can help lower their ...

Research Highlights: Use of an AI voice agent to prompt self-reported blood pressure readings helped to improve accuracy of blood pressure measures and patient outcomes in a group of majority ages 65 and older patients with high blood pressure. The study’s findings demonstrate how integrating AI into care can help to improve home blood pressure monitoring and completion rates, which can lead to improved quality outcomes for patients. Note: The study featured in this news release is a research abstract. Abstracts presented at the American Heart Association’s scientific meetings are not peer-reviewed, and the findings are considered preliminary until published ...

About The Study: In a large sample of U.S. children born between 1959 and 1966, higher blood pressure (BP) at age 7 was associated with greater risk of premature cardiovascular disease (CVD) mortality. These findings build upon prior research that linked childhood systolic BP with fatal CVD in young adulthood, but that sample had a follow-up duration through a mean age of only 46 years. This study extends that work with follow-up into the mid-50s and demonstrated consistency in the magnitude of the associations within siblings, which mitigates concerns regarding unmeasured confounding due to shared family or lifestyle characteristics. Corresponding ...

(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2 ) — Zidesamtinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing, demonstrated clinically meaningful activity and durability in patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) who had progressed on prior TKI therapy.  ROS1-positive NSCLC occurs in approximately 1–2% of all NSCLC cases. The results from the Phase ...

(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2 ) — Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ALK+ NSCLC, according to results from the Phase 3 E4512 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). The trial, conducted within the ALCHEMIST clinical trials program, ...

Ivonescimab Plus Chemotherapy Improves Progression-Free Survival in Patients with EGFR+ NSCLC Following 3rd-Generation EGFR-TKI Therapy (Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) — Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs). Results from the global Phase 3 HARMONi trial were presented today by Jonathan ...

(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC). These findings, presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer, support osimertinib plus chemotherapy as a new standard-of-care ...

Contact: Chris Martin, MPH IASLC Media Relations cmartin@davidjamesgroup.com (Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) – New results from the ACROSS 2 Phase III trial demonstrate that aumolertinib combined with platinum-pemetrexed chemotherapy significantly improves progression-free survival compared to aumolertinib monotherapy in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations and concomitant tumor suppressor gene mutations. The results were presented by Dr. Jie Wang, National Cancer Center, ...

Contact: Chris Martin, MPH/IASLC Media Relations/cmartin@davidjamesgroup.com (Barcelona, Spain — September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). Iza-bren is a first-in-class EGFR x HER3 bispecific ADC linked to a novel topoisomerase I inhibitor payload (Ed-04). The drug was evaluated ...

Iza-Bren in combination with Osimertinib Shows 100% Response Rate in EGFR-Mutated NSCLC, Phase II Study Finds Barcelona, Spain (September, 2025) —A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a 100% objective response rate (ORR) in patients with first-line EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). This study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC). Iza-bren is a first-in-class ADC combining EGFR and HER3 targeting with a topoisomerase I inhibitor payload. The study tested iza-bren at multiple ...

(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy. The study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC). The COMPEL study is a global, randomized, double-blind trial, in which adult patients with non-CNS progression on first-line osimertinib were randomized 1:1 to receive either osimertinib ...

(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — An analysis from the Phase 3 CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including those with Stage III N2 disease. These results were presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC). The study assessed HRQoL by nodal status and surgical outcomes using patient-reported outcome (PRO) measures such as the NSCLC-Symptom Assessment Questionnaire (NSCLC-SAQ) and the EQ-5D-3L visual ...

(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) validates the use of Sybil, a deep learning artificial intelligence model, for predicting future lung cancer risk in a predominantly Black population. The study, conducted by the University of Illinois Hospital & Clinics, (UI Health), the academic health enterprise of the University of Illinois Chicago (UIC), highlights Sybil’s strong performance in a real-world clinical setting with racially and socioeconomically ...

Research Highlights: Results from the FigHTN Phase 2 clinical trial showed baxdrostat, a new medication that inhibits the production of the hormone aldosterone, lowered systolic blood pressure by about 5% when added to the existing medications taken by people with chronic kidney disease and who also have uncontrolled high blood pressure. The analysis also found that baxdrostat lowered the loss of albumin in the urine, which is a marker of kidney and cardiovascular risk, by 55% compared to placebo, suggesting that this medication may help delay the progression of kidney disease . These findings suggest the potential for baxdrostat to improve longer-term health outcomes like kidney and ...

  The integration of oncolytic viruses (OVs) with immunotherapy is reshaping the landscape of tumor treatment, offering new hope for patients. This cutting-edge approach harnesses the ability of OVs to selectively infect and destroy tumor cells, while simultaneously stimulating anti-tumor immune responses. The latest advancements in genetic engineering have further optimized these therapies, leading to improved clinical outcomes and enhanced patient quality of life.   By combining OVs with cellular immunotherapy, immune checkpoint inhibitors, cancer vaccines, cytokines, and bi- or tri-specific T cell engagers, researchers have developed innovative ...

  Head and neck cancer remains a major global health challenge, ranking among the six most common cancers worldwide and claiming hundreds of thousands of lives each year. A growing body of evidence now points to an intricate connection between energy metabolism and immune regulation as a driving force behind the onset, progression, and treatment resistance of these cancers. The latest comprehensive review on this topic underscores the potential of targeting these intertwined processes to unlock more effective therapies.   Tumor cells in head and neck cancer exhibit profound metabolic reprogramming, altering the way they process glucose, lipids, and ...

BATON ROUGE – Pennington Biomedical Research Center is proud to announce that Dr. Steven B. Heymsfield, Professor of Metabolism and Body Composition, has been named a Boyd Professor of Louisiana State University – the highest faculty rank and honor awarded within the LSU System. The Boyd Professorship is reserved for faculty whose outstanding achievements and international reputations bring significant prestige to LSU. Dr. Heymsfield joins an elite group of scholars recognized for advancing knowledge and transforming ...

  Hed: Study prompts new theory of human-machine communication   LAWRENCE – In a new paper, two University of Kansas scholars propose a novel theory of communication analysis that takes into better account how people interact with ubiquitous technology in the 21st-century workplace. In “Socio-Technical Exchange with Machines: Worker Experiences with Complex Work Technologies,” ----- link to https://doi.org/10.30658/hmc.10.3 ----------- in the Human-Machine Communications ...

UNIVERSITY PARK, Pa. — Essentially all cells in an organism’s body have the same genetic blueprint, or genome, but the set of genes that are actively expressed at any given time in a cell determines what type of cell it will be and its function. How rapidly gene expression in a single cell changes over time can provide insight into how cells might become more specialized, but current measurement approaches are limited. A new method developed by researchers at Penn State and Yale University incorporates spatial information from the cell as well as data from cells processed at different times, improving researchers’ ability to understand the nuances of gene expression ...

The movement of genetic material between organisms that aren’t directly related is a significant driver of evolution, especially among single-celled organisms like bacteria and archaea. A team led by researchers at Bigelow Laboratory for Ocean Sciences have now estimated that an average cell line acquires and retains roughly 13 percent of its genes every million years via this process of lateral gene transfer. That equates to about 250 genes swapped per liter of seawater every day. The new study, recently published in The ISME Journal, provides the first quantitative analysis of gene transfer rates across an entire microbiome. It calls into question the strict classification ...

The U.S. Air Force awarded startup SkyNano, led by Innovation Crossroads alumna Anna Douglas, a $1.25 million contract to advance its CO2-to-carbon nanotube technology as part of a project to develop low-cost, battery-grade graphite. SkyNano’s partners include American Energy Technologies Company and Eonix, led by Innovation Crossroads alumnus Don DeRosa. SkyNano and Eonix were recruited to Knoxville through Innovation Crossroads, a Lab-Embedded Entrepreneurship Program node at Oak Ridge National Laboratory.  “In addition to accessing ...

Some of the populations with the highest risk for Alzheimer’s disease remain greatly underrepresented in clinical trials—and a new study helps explain why. Researchers from the Keck School of Medicine of USC found that participants from these high-risk groups are less likely to have elevated amyloid in the brain based on blood levels of p-tau217.  Elevated amyloid is a requirement for clinical trials of Alzheimer’s disease treatments, and amyloid is known to accumulate in the brain years before any signs of cognitive decline. The study, funded in part by the National Institutes of Health (NIH), builds on earlier research with similar findings, but leverages ...

    This review article highlights the transformative potential of in vivo CAR T cell therapy in addressing the limitations of traditional CAR T cell production. This innovative approach could revolutionize cancer treatment, offering a more efficient, scalable, and cost-effective alternative to conventional methods.   CAR T cell therapy has shown remarkable success in treating hematological malignancies; however, current production methods are laborious, time-consuming, and expensive. Traditional in vitro CAR T cell production typically requires 2–3 weeks and involves complex processes, including T cell isolation, activation, genetic modification, ...

  Recent advances in cancer treatment highlight the potential of natural medicines to target the tumor vascular microenvironment, offering a novel strategy to inhibit tumor growth and metastasis. Unlike conventional therapies that directly target tumor cells, natural compounds focus on normalizing tumor vasculature and inhibiting pathological angiogenesis, crucial processes in cancer progression. This innovative approach holds promise in enhancing anti-cancer therapies while minimizing side effects.   The tumor vascular microenvironment plays a pivotal role in cancer development. Tumor blood vessels are often irregular, immature, ...

In the depths of the ocean, marine corals have evolved intricate, porous structures that shelter diverse microbial communities. Now, researchers have borrowed this biological blueprint to create an ingestible pill that can sample bacteria from one of the most inaccessible regions of the human body: the small intestine. The CORAL (Cellularly Organized Repeating Lattice) capsule, developed by Khalil Ramadi – assistant professor of bioengineering at NYU Tandon School of Engineering and NYU Abu Dhabi (NYUAD) – and ...